Non-Endocytic Membrane-Translocating Delivery Strategies Bypass Endosomal Barriers for Gene, mRNA, and Protein Therapies

Drug Target Review UK

Overview

A new review evaluates non-endocytic membrane-translocating delivery strategies designed to circumvent insufficient endosomal escape efficiency, a major hurdle for many next-generation therapeutics. These emerging platforms aim to improve the efficacy of gene therapy, mRNA therapy, and protein-based medicines by directly transporting therapeutic biomacromolecules into the cytoplasm, bypassing conventional cellular uptake pathways. This approach holds the potential to unlock a critical bottleneck in intracellular delivery and dramatically enhance the therapeutic impact of nucleic acid medicines.

In Depth

Key Findings: Non-Endocytic Membrane-Translocating Delivery Strategies Overcome Endosomal Barriers for Gene, mRNA, and Protein Therapies

A new review article published in Drug Target Review highly praises non-endocytic membrane-translocating delivery strategies as a groundbreaking approach to bypass ‘insufficient endosomal escape efficiency,’ which has been a major obstacle for many next-generation therapeutics, particularly nucleic acid and protein-based medicines. These emerging platforms hold the potential to dramatically improve the efficacy of gene therapy, mRNA therapy, and protein-based medicines by directly transporting therapeutic biomacromolecules into the cytoplasm, circumventing conventional cellular uptake pathways.

Technical and Clinical Details: Direct Cytoplasmic Delivery Bypasses the Need for Endosomal Escape

One of the primary mechanisms by which cells internalize external molecules is endocytosis. However, many therapeutic biomacromolecules taken up via endocytosis face the challenge of being degraded within endosomes or failing to escape effectively before reaching the cytoplasm. This ‘endosomal trap’ has severely limited the efficacy of gene therapy vectors, mRNA-LNPs (lipid nanoparticles), and antibodies targeting intracellular proteins, among others.

Non-endocytic membrane-translocating delivery strategies aim to fundamentally resolve this bottleneck. Specifically, the review evaluates technologies such as:

• Cell-Penetrating Peptides (CPPs): Peptides that bind directly to cell membranes and possess the ability to transport therapeutic molecules into the cytoplasm. CPPs have been applied in the delivery of gene editing tools (e.g., CRISPR/Cas9), proteins, and nucleic acids.
• Virus-Derived Membrane Fusion Proteins: Some viruses have mechanisms to directly fuse with cell membranes and release genetic material into the cytoplasm. Designing molecules that mimic this mechanism allows for drug delivery without going through the endosomal pathway.
• Physical Delivery Methods: Physical techniques such as microinjection and electroporation are also used to temporarily permeabilize cell membranes and directly introduce therapeutics into the cytoplasm, although these are primarily applied in vitro or ex vivo.

These emerging platforms offer the advantage that drugs are protected from the acidic environment and enzymatic degradation within endosomes, allowing them to exert maximum therapeutic effect in the cytoplasm. Especially for nucleic acid medicines like mRNA therapies and gene editing technologies, which need to function in the cytoplasm, improving endosomal escape efficiency is a critically important challenge.

Background and Industry Context: The Rise of Nucleic Acid Medicines and Intracellular Therapies

Nucleic acid medicines (gene therapy, mRNA therapy, siRNA, etc.) and protein-based medicines targeting intracellular pathways hold the potential to revolutionize disease treatment, but intracellular delivery has long been a major challenge. Specifically, crossing the double barrier of the cell membrane and endosomal membrane has limited the clinical application of these drugs. Existing delivery systems such as viral vectors and lipid nanoparticles often utilize the endosomal pathway, and endosomal escape efficiency frequently becomes the rate-limiting step. Non-endocytic delivery strategies are pursuing this ‘holy grail’ of delivery and are positioned as critical technological innovations that will determine the clinical success of nucleic acid medicines.

Future Outlook: Dramatic Enhancement of Therapeutic Efficacy and Broad Disease Application

Further advancements in non-endocytic membrane-translocating delivery strategies hold the potential to dramatically enhance the efficacy of gene therapy, mRNA therapy, and treatments targeting intracellular proteins. If the safety, specificity, and scalability of these technologies are further improved, new therapeutic options will emerge for a wider range of disease areas, particularly cancer, genetic disorders, and neurodegenerative diseases. For example, if gene editing tools like CRISPR/Cas9 can be efficiently delivered directly to the cell nucleus, the applicability and success rate of gene therapy will significantly increase. This innovative approach is expected to accelerate the clinical success of next-generation medicines and be a key driver in substantially improving patients’ quality of life.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime